Loss of hMLH1 expression correlates with improved survival in stage III-IV ovarian cancer patients

European Journal of Cancer

Volumn 39, Issue 8, 2003, Pages 1144-1149

  Scartozzi, M ^a   De Nictolis, M ^a   Galizia, E ^a   Carassai, P ^a   Bianchi, F ^a   Berardi, R ^a   Gesuita, R ^b   Piga, A ^a   Cellerino, R ^a   Porfiri, E ^a  

^a Ospedale Regionale Torrette   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Advanced ovarian cancer; Chemotherapy; hMLH1; Platinum resistance

Indexed keywords

CISPLATIN; GENE PRODUCT; PROTEIN MLH1;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; GENE EXPRESSION; GENE LOSS; HUMAN; HUMAN TISSUE; MISMATCH REPAIR; MULTIVARIATE ANALYSIS; OVARY CANCER; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME;

EID: 0037726780     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(03)00197-7     Document Type: Article

References (18)

1. Daly M., Obrams G.I. Epidemiology and risk assessment for ovarian cancer. Semin. Oncol. 25:1998;255-264.
2. Landis S.H., Murray T., Bolden S., Wingo P.A. Cancer Statistics 1998. CA Cancer J. Clin. 48:1998;6-29.
3. Ozols R.F., Schwartz P.E., Eifel P.J. Ovarian cancer, fallopian tube carcinoma and peritoneal carcinoma. De Vita V.T. Jr., Hellman S., Rosenberg S.A. Cancer: Principles & Practice of Oncology. 6th edn. 2001;1597-1632 Philadelphia, Lippincott-Raven.
4. Auersperg N., Edelson M.I., Mok S.C., Johnson S.W., Hamilton T.C. The biology of ovarian cancer. Semin. Oncol. 25:1998;281-304.
5. Aebi S., Kurdi-Haidar B., Gordon R.et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res. 56:1996;3087-3090.
6. Colella G., Marchini S., D'Incalci M., Brown R., Broggini M. Mismatch repair deficiency is associated with resistance to DNA minor groove alkylating agents. Br. J. Cancer. 80:1999;338-343.
7. Fink D., Nebel S., Norris P.S.et al. The effect of different chemotherapeutic agents on the enrichment of DNA mismatch repair-deficient tumor cells. Br. J. Cancer. 77:1998;703-708.
8. Vikhanskaya F., Colella G., Valenti M., Parodi S., D'Incalci M., Broggini M. Cooperation between p53 and hMLH1 in human colocarcinoma cell line in response to DNA damage. Clin. Cancer Res. 5:1999;937-941.
9. Plumb J.A., Strathdee G., Sludden J., Kaye S.B., Brown R. Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res. 60:2000;6039-6044.
10. Branch P., Masson M., Aquilina G., Bignami M., Karran P. Spontaneous development of drug resistance. mismatch repair and p53 defects in resistance to cisplatin in human tumor cells Oncogene. 19:2000;3138-3145.
11. Samimi G., Fink D., Varki N.M.et al. Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy. Clin. Cancer Res. 6:2000;1415-1421.
12. Mackay H.J., Cameron D., Rahilly M.et al. Reduced MLH1 expression in breast tumors after primary chemotherapy predicts disease-free survival. J. Clin. Oncol. 18:2000;87-93.
13. Paulson T.G., Wright F.A., Parker B.A., Russack V., Wahl G.M. Microsatellite instability correlates with reduced survival and poor disease prognosis in breast cancer. Cancer Res. 56:1996;4021-4026.
14. Gryfe R., Kim H., Hsieh E.T.K.et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N. Engl. J. Med. 342:2000;69-77.
15. Chiaravalli A.M., Furlan D., Facco C.et al. Immunohistochemical pattern of hMSH2/hMLH1 in familial and sporadic colorectal, gastric, endometrial and ovarian carcinomas with instability in microsatellite sequences. Virchows Arch. 428:2001;39-48.
16. Fink D., Nebel S., Aebi S.et al. Expression of the DNA mismatch repair proteins hMLH1 and hPMS2 in normal human tissues. Br. J. Cancer. 76:1997;890-893.
17. Cawkwell L., Gray S., Murgatroyd H.et al. Choice of management strategy for colorectal cancer based on a diagnostic immunohistochemical test for defective mismatch repair. Gut. 45:1999;409-415.
18. Saphir A. Pathology vs. prognosis. are hereditary cancers a different breed? J. Natl. Cancer Inst. 90:1998;880-882.